• XORTX outlined a plan to file a U.S. NDA for gout candidate XRx-026 in H2 2027, targeting allopurinol-intolerant patients.
• Presentation cited safety and efficacy data in more than 700 patients, positioning oxypurinol as an allopurinol alternative.
• Commercial framing centered on a gap left by febuxostat’s black box warning, citing a more than USD 0.7 billion peak sales opportunity.
• ADPKD candidate XRx-008 positioned for registration trials under accelerated approval and orphan designation in a market described as more than USD 5 billion.
• Cap table showed 1,730,565 common shares outstanding, 3,830,120 warrants, 24,854 options, 5,585,539 fully diluted shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.